Three-dimensional reconstruction technique for evaluation of tumor burden and future remnant liver in patients with hepatocellular carcinoma undergoing liver resection
AbstractIntroduction: Hepatic resection is the mainstay of treatment for Hepatocellular carcinoma (HCC). Three- dimensional technique helps to create an image of the liver using pre-operative computed tomography (CT) scans which can be used for planning of surgery and counselling of the patient. Various lab parameters have also been shown to affect the prognosis of HCC. This study was designed to analyse whether three dimensional technique and blood parameters are correlated with the prognosis among HCC patients following hepatic resection and also to find a relation between these variables.Methods: Data were collected retrospectively to recruit HCC patients treated between January 2010 and December 2016. Seventy-three HCC patients without extrahepatic metastasis, who underwent hepatic resection and had pre-operative CT scan done in our centre were enrolled for this study. IQQA® was used to create a three-dimensional imaging, and various related laboratory parameters were also collected. Outcomes of these patients were calculated to establish a relationship between IQQA, laboratory results and the prognosis of the patients.Results: The one, three and five year overall survival (OS) rates were 94.4%, 53.3% and 19.4% respectively, and disease-free survival (DFS) rates were 75%, 31.3% and 12.8% respectively. IQQA percentage of tumor was statistically significant for both OS and DFS. In the multivariate analysis, patients having lymph node metastasis, vascular invasion and high pre-op CA 19-9 had lower DFS rate, while it increased in those with high pre-op albumin. Other significant variables for OS were lymph node metastasis, Child Pugh score, high pre-op alpha fetoprotein (AFP) value and high CA 19-9. Resected segments, lymph node metastasis, liver cirrhosis, blood loss and hospital stay were significant between the two IQQA subgroups (IQQA?30% and IQQA>30%). Additionally in these IQQA subgroups, significant difference was found between DFS and OS.Conclusion: IQQA software is helpful to create a 3D image of the liver, and can be combined with lab parameters to predict prognosis for patients with liver cancer. Therefore, this three-dimensional imaging technique can be used as a routine technique for patients undergoing liver resection.
2. Gao S-Y, Tang L, Cui Y, Li X-T, Zhang X-Y, Shan J, et al. Tumor angiogenesis-related parameters in multi-phase enhanced CT correlated with outcomes of hepatocellular carcinoma patients after radical hepatectomy. Eur J Surg Oncol EJSO 2016;42(4):538-44. PMID: 26852106.
3. Lee W-C, Chen M-F. Assessment of hepatic reserve for indication of hepatic resection: how I do it. J Hepatobiliary Pancreat Surg 2005;12(1):23-6. PMID: 15754098.
4. Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Iacono C. How Much Remnant Is Enough in Liver Resection? Dig Surg 2012;29(1):6-17. PMID: 22441614.
5. Tang J-H, Yan F-H, Zhou M-L, Xu P-J, Zhou J, Fan J. Evaluation of Computer-Assisted Quantitative Volumetric Analysis for Pre-Operative Resectability Assessment of Huge Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2013;14(5):3045-50. PMID: 23803077.
6. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19(3):329-38. PMID: 10518312.
7. Liu P-H, Hsu C-Y, Lee Y-H, Su C-W, Hsia C-Y, Huang Y-H, et al. Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma: Special Emphasis on Viral Etiology. Medicine (Baltimore) 2015;94(41):e1772. PMID: 26469917.
8. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatol Baltim Md 1998;28(3):751-5. PMID: 9731568.
9. Okuda K, Obata H, Nakajima Y, Ohtsuki T, Okazaki N, Ohnishi K. Prognosis of primary hepatocellular carcinoma. Hepatol Baltim Md 1984;4(1 Suppl):3S-6S. PMID: 6319264.
10. Leung TWT, Tang AMY, Zee B, Lau WY, Lai PBS, Leung KL, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002;94(6):1760-9. PMID: 11920539.
11. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38(3):207-15. PMID: 12673442.
12. Wang J, Xu L, Liu C, Pang H, Chen Y, Ou Q. Prognostic Factors and Outcome of 438 Chinese Patients with Hepatocellular Carcinoma Underwent Partial Hepatectomy in a Single Center. World J Surg 2010;34(10):2434-41. PMID: 20523993.
13. Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A. A laboratory marker, FIB-4 index, as a predictor for long-term outcomes of hepatocellular carcinoma patients after curative hepatic resection. Surgery 2015;157(4):699-707. PMID: 25704421.
14. Zhong J, Ke Y, Gong W, Xiang B, Ma L, Ye X, et al. Hepatic Resection Associated With Good Survival for Selected Patients With Intermediate and Advanced-Stage Hepatocellular Carcinoma. Ann Surg 2014;260(2):329-40. PMID: 24096763.
15. Faber W, Sharafi S, Stockmann M, Denecke T, Sinn B, Puhl G, et al. Long-term results of liver resection for hepatocellular carcinoma in noncirrhotic liver. Surgery 2013;153(4):510-7. PMID: 23122930.
16. Li M, Zhao H, Bi X, Li Z, Huang Z, Han Y, et al. Total tumor volume predicts survival following liver resection in patients with hepatocellular carcinoma. Tumor Biol 2016;37(7):9301-10. PMID: 26779628.
17. Zhang WW, Wang HG, Shi XJ, Chen MY, Lu SC. [Significance of three-dimensional reconstruction as a method of preoperative planning of laparoscopic radiofrequency ablation]. Zhonghua Wai Ke Za Zhi 2016;54(9):692-9. PMID: 27587213.
18. Chen L, Luo HP, Dong SL, Chen XP. [Safety assessment of hepatectomy for huge hepatocellular carcinoma by three dimensional reconstruction technique]. Zhonghua Wai Ke Za Zhi 2016;54(9):669-74. PMID: 27587209.
19. Alkhalili E, Greenbaum A, Luo L, Rodriguez R, Caldwell K, Estrada OM, et al. Viral hepatitis status does not affect survival in patients with hepatocellular carcinoma. Ann Gastroenterol 2017;30(1):101-5. PMID: 28042245.
20. Befeler AS, Palmer DE, Hoffman M, Longo W, Solomon H, Di Bisceglie AM. The safety of intra-abdominal surgery in patients with cirrhosis: model for end-stage liver disease score is superior to Child-Turcotte-Pugh classification in predicting outcome. Arch Surg Chic Ill 1960 2005;140(7):650-4; discussion 655. PMID: 16027329.
21. Wu CC, Ho WL, Lin MC, Tang JS, Yeh DC, Liu TJ, et al. Is hepatic resection absolutely contraindicated for hepatocellular carcinoma in Child-Pugh class C cirrhotic patients? Hepatogastroenterology 1999;46(26):635-9. PMID: 10370588.
22. Kudo M, Kitano M, Sakurai T, Nishida N. General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of Japan. Dig Dis Basel Switz 2015;33(6):765-70. PMID: 26488173.
23. Park YK, Song SK, Kim B-W, Park S-K, Chung C-W, Wang H-J. Prognostic significance of microvascular invasion in tumor stage for hepatocellular carcinoma. World J Surg Oncol 2017;15(1):225. PMID: 29258507.
24. Masuda T, Beppu T, Ishiko T, Horino K, Baba Y, Mizumoto T, et al. Intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy. J Hepatobiliary Pancreat Surg 2008;15(6):589-95. PMID: 18987928.
25. Santambrogio R, Opocher E, Costa M, Barabino M, Zuin M, Bertolini E, et al. Hepatic resection for "BCLC stage A" hepatocellular carcinoma. The prognostic role of alpha-fetoprotein. Ann Surg Oncol 2012;19(2):426-34. PMID: 21732145.
26. Kim HS, Park JW, Jang JS, Kim HJ, Shin WG, Kim KH, et al. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. J Clin Gastroenterol 2009;43(5):482-8. PMID: 19197197.
27. Chen Y-L, Chen C-H, Hu R-H, Ho M-C, Jeng Y-M. Elevated preoperative serum CA19-9 levels in patients with hepatocellular carcinoma is associated with poor prognosis after resection. ScientificWorldJournal 2013;2013:380797. PMID: 23843733.
28. Xia F, Wu L, Lau W-Y, Li G, Huan H, Qian C, et al. Positive lymph node metastasis has a marked impact on the long-term survival of patients with hepatocellular carcinoma with extrahepatic metastasis. PloS One 2014;9(4):e95889. PMID: 24760012.
29. Hasegawa K, Makuuchi M, Kokudo N, Izumi N, Ichida T, Kudo M, et al. Impact of histologically confirmed lymph node metastases on patient survival after surgical resection for hepatocellular carcinoma: report of a Japanese nationwide survey. Ann Surg 2014;259(1):166-70. PMID: 23532111.
30. Wu T, Ma X-A, Wang G-Q, Li Q, Li M-J, Guo J-Y, et al. ABO blood type correlates with survival in hepatocellular carcinoma following hepatectomy. Sci Rep 2017;7(1):4412. PMID: 28667286.
31. Gao F, Li X, Geng M, Ye X, Liu H, Liu Y, et al. Pretreatment neutrophil-lymphocyte ratio: an independent predictor of survival in patients with hepatocellular carcinoma. Medicine (Baltimore) 2015;94(11):e639. PMID: 25789957.
32. Akahoshi H, Taura N, Ichikawa T, Miyaaki H, Akiyama M, Miuma S, et al. Differences in prognostic factors according to viral status in patients with hepatocellular carcinoma. Oncol Rep 2010;23(5):1317-23. PMID: 20372846.
33. Trevisani F, Magini G, Santi V, Morselli-Labate AM, Cantarini MC, Di Nolfo MA, et al. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol 2007;102(5):1022-31. PMID: 17313497.
34. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007;47(6):760-7. PMID: 17928090.
35. Li Bin, Yu Yao, He Yifeng, Fan Jia, Wu Zhiquan, Zhou Wei, et al. Value of the conventional liver function tests in the assessment of hepatic reserve. Chin J Hepatobiliary Surg 2011;2011(10):805-8. DOI: 10.3760/cma.j.issn.1007-8118.2011.10.004.
36. Strasak AM, Rapp K, Brant LJ, Hilbe W, Gregory M, Oberaigner W, et al. Association of gamma-glutamyltransferase and risk of cancer incidence in men: a prospective study. Cancer Res 2008;68(10):3970-7. PMID: 18483283.
37. Hann H-W, Wan S, Myers RE, Hann RS, Xing J, Chen B, et al. Comprehensive Analysis of Common Serum Liver Enzymes as Prospective Predictors of Hepatocellular Carcinoma in HBV Patients. PLoS ONE 2012;7(10):e47687. PMID: 23112834.
38. Nojiri S, Joh T. Albumin suppresses human hepatocellular carcinoma proliferation and the cell cycle. Int J Mol Sci 2014;15(3):5163-74. PMID: 24663086.
39. Nojiri S, Kusakabe A, Shinkai N, Matsuura K, Iio E, Miyaki T, et al. Factors influencing distant recurrence of hepatocellular carcinoma following combined radiofrequency ablation and transarterial chemoembolization therapy in patients with hepatitis C. Cancer Manag Res 2011;3:267-72. PMID: 21847355.
40. Wan G, Gao F, Chen J, Li Y, Geng M, Sun L, et al. Nomogram prediction of individual prognosis of patients with hepatocellular carcinoma. BMC Cancer 2017;17(1):91. PMID: 28143427.
41. Ji F, Liang Y, Fu S-J, Guo Z-Y, Shu M, Shen S-L, et al. A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI). BMC Cancer 2016;16:137. PMID: 26907597.
42. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JPA, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 2008;32(8):1757-62. PMID: 18340479.
43. Zheng Y-B, Zhao W, Liu B, Lu L-G, He X, Huang J-W, et al. The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev APJCP 2013;14(9):5527-31. PMID: 24175853.
44. Lee SS, Shin HS, Kim HJ, Lee SJ, Lee HS, Hyun KH, et al. Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience. Korean J Hepatol 2012;18(1):48-55. PMID: 22511903.
45. Long TCD, Bac NH, Thuan ND, Dat LT, Viet DQ, Chuong LCHQ. Laparoscopic liver resection: 5-year experience at a single center. Surg Endosc 2014;28(3):796-802. PMID: 24196550.
46. Jiang CL, Tang D, Wang Y, Liang LJ, Ren QQ, Kuang M. Application of a three-dimensional operation planning system for precise hepatectomy in patients with giant hepatocellular carcinoma. Chin J Dig Surg 2012;11(2):111-5. DOI: 10.3760/cma.j.issn.1673-9752.2012.02.006.
47. Wang JD, Shen J, Zhou XP, Zhuang YP, Zhou Di, Yang Y, et al. Comprehensive measures for improving the radical resection rate and safety of Bismuth-Corlette type ? hilar cholangiocarcinoma. Chin J Surg 2013;51(7):596-9. PMID: 24256583.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright and Open Access Policy
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
JSSN applies the Creative Commons Attribution (CC BY) license to all works we publish. Under the CC BY license, authors retain ownership of the copyright for their article, but authors allow anyone to download, reuse, reprint, distribute, and/or copy articles in JSSN, so long as the original authors and source are cited. No permission is required from the authors or the publishers.
Article by JSSN is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at http://www.jssn.org.np/index.php?journal=jssn.